Despite an explosion in the number of drugs and treatment strategies available, pulmonary arterial hypertension is still a rapidly fatal condition for a small, hard to identify patient group. A small clinical elite is currently leading the way in advancing treatment outcomes, and is central to determining which new treatment strategies are used.
Scope
Defining the key clinical characteristics of the pulmonary arterial sector that present a unique commercial challenge
Translation of critical clinical issues into pertinent practical considerations for both incumbent players and new market entrants
Insight into the challenge of determining a patient potential in the context of a miniscule diagnosed population and a phenomenal at-risk population
Assessment of future directions in management and the changing roles of therapies
Highlights
The estimated 8,11516,186 diagnosed pulmonary arterial hypertension patients across the US, Japan, France, Germany, Italy, Spain and the UK represent a fraction of the 28.0135.6 million group known to be at elevated risk. Identifying the true patient potential within known high risk groups remains highly problematic.
A small, but relatively powerful clinical community has brought structure, order and an increasing influence to bear on management through a few specialist centers. This internationally cohesive group has been responsible for laying the foundations for substantial volumes of data pertaining to patients managed in increasingly standardized ways.
A high number of approved and late stage pipeline products, and the increasing exploration of combination therapeutics places a higher emphasis than normal on the perceptions of specialist clinicians, who will increasingly need to triage their attentions to the most promising avenues for improving outcomes.
Reasons to Purchase
Understand the challenges in aligning product positioning to the demands of the future clinical paradigm
Identify development strategies that allow optimal buy-in from an increasingly important clinical community
Qualify market expectations against the practical realities of targeting this fragmented, niche patient population
(0 items)
